ABSTRACT

Heterozygous activating mutations of KCNJ11 (Kir6.2) are the most common cause of permanent neonatal diabetes mellitus (PNDM) and several cases have been successfully treated with oral sulfonylureas. We report on the attempted transfer of insulin therapy to glibenclamide in a 4-year-old child with PNDM and DEND syndrome, bearing a C166Y mutation in KCNJ11. An inpatient transition from subcutaneous NPH insulin (0.2 units/kg/d) to oral glibenclamide (1 mg/kg/d and 1.5 mg/kg/d) was performed. Glucose and C-peptide responses stimulated by oral glucose tolerance test (OGTT), hemoglobin A1c levels, the 8-point self-measured blood glucose (SMBG) profile and the frequency of hypoglycemia episodes were analyzed, before and during treatment with glibenclamide. Neither diabetes control nor neurological improvements were observed. We concluded that C166Y mutation was associated with a form of PNDM insensitive to glibenclamide. (Arq Bras Endocrinol Metab 2008; 52/8:1350-1355)

Keywords: Neonatal diabetes mellitus; KATP channels; KCNJ11; C166Y mutation; Glibenclamide; Treatment failure

INTRODUCTION

Neonatal diabetes mellitus (NDM) is a rare condition with an estimated incidence of 1:300,000 to 1:500,000 live births (1-4), defined as persist-
tent hyperglycemia occurring within the first 6 months of life, lasting more than 2 weeks and requiring insulin therapy (5), and accordingly to the subsequent clinical course, it will be classified as permanent or transient (1).

Transient neonatal diabetes mellitus (TNDM) comprises approximately 50% of the cases and usually resolves in the first 18 months of life although requiring insulin therapy until resolution (2,4,5); approximately one fourth of such cases will relapse from 7 to 20 years later (5).

Heterozygous activating mutations of KCNJ11 and ABCC8 are responsible for approximately 50% of permanent NDM (PNDM) (6-9). Defects in several other genes (IPF1, GCK, HNF1B, INS, FOXP3, EIF2AK3) have also been implicated in PNDM (4,9), however the activating mutations of KCNJ11, which reduce the ability for ATP to close the ATP-sensitive potassium channel (K_{ATP}), are the most common (6).

Glucose-stimulated insulin secretion is regulated by the closing of K_{ATP} channel which is an octameric complex of four pore-forming, inwardly rectifying potassium-channel subunits (Kir6.2) encoded by KCNJ11 gene and four regulatory sulfonylurea-receptor subunits (SUR1) encoded by ABCC8 gene (10,11).

Sulfonylureas have affinity to SUR1 and stimulate insulin secretion by an ATP-independent mechanism and can successfully replace insulin therapy to achieve a better metabolic control in several PNDM cases due to KCNJ11 mutations (6,12). So the identification of a KCNJ11 mutation has implications for clinical management since many patients have been treated successfully with oral sulphonylureas rather than insulin (12-17). Here we describe a case of a Brazilian child with PNDM and DEND syndrome (Developmental Delay, Epilepsy, Neonatal Diabetes) (18) due to a C166Y mutation in KCNJ11 gene and the results of the attempted transfer from insulin therapy to oral glibenclamide.

SUBJECTS AND METHODS

A Brazilian female child was born at 38 wk of gestation to a gravida 1 para 1 mother, whose pregnancy was uncomplicated, with a birth weight of 3000 g, length of 48 cm and Apgar score: 8 and 9. Her healthy parents were unrelated and the family history was remarkable for maternal grandparents with adult-onset diabetes and an aunt with diabetes and epilepsy. The postnatal course was uncomplicated and she was discharged home in the third day of life.

She was doing well until 3 months old when she manifested an exaggerated crying with irritability, and one month later she exhibited repeated head and limbs spasms followed by drowsiness. After physical and neurological examination, failure to thrive, muscle weakness, hypotonia and development delay were evident. A subsequent electroencephalogram showed slow background activity with multifocal spikes and slow wave complexes and then she was initiated on valproic acid (40 mg/kg/d).

At the age of 5 months she developed fever, polyuria, irritability and laboratory work-up revealed glucosuria and a blood glucose level of 900 mg/dL; however, ketoacidosis was not documented. She received intravenous normal saline and was started on subcutaneous insulin therapy with NPH human insulin and fast-acting insulin analogue (lispro) to correct hyperglycemia. Six days later she was discharged home in use of NPH 1.5 IU in the morning and 1 IU at bedtime, clobazam (10 mg/d) and valproic acid (56 mg/kg/d).

The child was referred to our outpatient clinic at 13 months of age when she was not able to sit, speak syllables, or follow movements with eyes; her body weight was 8.000 g (-1.89 SDS), height was 71.5 cm (-1.88 SDS) and head circumference was 42.5 cm (-2.58 SDS). Anti-insulin and islet cell antibodies were negative.

At the age of 4 she presented failure to thrive (Weight= -3.3 SDS; Height= -4.2 SDS), microcephaly, severe development delay, muscle weakness, epilepsy, diabetes mellitus (Figure 1) and was classified as full DEND syndrome (18). A novel C166Y mutation in KCNJ11 was found by sequencing of the patient’s KCNJ11 gene using genomic DNA extracted from peripheral lymphocytes by standard methods (19).

Parents were informed of the possible glibenclamide-related side effects and written informed consent was obtained before study initiation and after approval by local ethics committee. An inpatient transition from subcutaneous human NPH insulin therapy (0.2 units/kg/d) to oral glibenclamide (1 mg/kg/d) was performed during a 4-week period followed by a washout phase with subcutaneous NPH insulin and a subsequent 4-week trial with a higher oral glibenclamide dose (1.5 mg/kg/d) (12). The primary outcome was insulin independence after a 4-week period on glibenclamide, with a maximum dose of 1.5 mg/kg/d. Correction bolus doses with fast-acting insulin analogue (lispro) were done every time blood glucose levels were ≥ 200 mg/dL.
Glucose and C-peptide stimulated by 2-hour oral glucose tolerance test (OGTT, 1.75 g/kg, standard method) were compared immediately before and after transition to oral glibenclamide (1 mg/kg/d). Hemoglobin A1c levels (HPLC, Bio-Rad Laboratories, Hercules, CA, USA), the 8-point self-measured blood glucose (SMBG) profile and the frequency of hypoglycemia episodes registered in Camit-Pro software for Accu-chek® glucometers were compared before and during treatment with glibenclamide (1 mg/kg/d), during subcutaneous NPH insulin washout phase and during reintroduction of a higher dose of glibenclamide (1.5 mg/kg/d). Data were expressed as mean ± SD; differences between groups were assessed by Student’s t-test and ANOVA, p<0.05 was considered significant.

Stimulated mean blood glucose level was significantly higher during glibenclamide (1 mg/kg/d) treatment than with NPH insulin therapy (250 ± 80 vs 160 ± 54 mg/dL; p<0.01) and no difference between stimulated mean plasma C-peptide (0.46 ± 0.26 vs 0.26 ± 0.22 ng/mL) response was observed during oral glibenclamide and NPH insulin therapy, respectively (Figure 2). Another OGTT with oral glibenclamide (1.5 mg/kg/d) was not performed.

Neither hemoglobin A1c levels, nor the 8-point SMBG profile and frequency of hypoglycemic events were different during oral glibenclamide (1 and 1.5 mg/kg/d) and NPH insulin therapy, respectively (Figures 3, 4 and 5). No side effects related to glibenclamide or neurological improvement were observed; however correction boluses of lispro insulin were required once to four times a day during glibenclamide treatment.

Since insulin independence was not achieved, the child returned on NPH and lispro insulin therapy and now is maintaining an adequate metabolic control.

**DISCUSSION**

The effectiveness of oral sulfonylurea in improving glycemic control of diabetic patients due to KCNJ11 mutations after transfer from insulin therapy has been confirmed by many reports, with doses ranging from 0.05 to 1.5 mg/kg/d (12-17); however data concerning the use of sulfonylurea in the treatment of PNDM with DEND syndrome have shown variable results. Several mutations related to severe DEND syndrome (Q52R, G53R, V59G, I296L, G334D) are insensitive to glibenclamide (4,12,19,20); nevertheless in some forms of intermediate DEND syndrome (I167L, G53D, H46L, V59M), characterized by less severe developmental delay and without epilepsy, glibenclamide therapy has improved metabolic control, neuromuscular symptoms (17,21-24) and even cognition (V59M) (25). Evidence that sulfonylurea could change CNS blood flow and function was provided by the use of...
Figure 2. Comparison of OGTT-stimulated glucose and plasma C-peptide responses during NPH insulin therapy (0.2 units/kg/d) and glibenclamide (GCD) (1 mg/kg/d). (Student t test).

Figure 3. Comparison of HbA1c during NPH insulin therapy and oral glibenclamide (GCD) 1mg/kg/d and 1.5 mg/kg/d. (ANOVA).

Figure 4. Comparison of OGTT-stimulated glucose and plasma C-peptide responses during NPH insulin therapy (0.2 units/kg/d) and glibenclamide (GCD) (1 mg/kg/d). (Student t test).

Figure 5. Comparison of hypoglycemia frequency during NPH insulin therapy and oral glibenclamide (GCD) 1mg/kg/d and 1.5 mg/kg/d. (ANOVA).
single-photon emission CT (SPECT) imaging, before and after glibenclamide therapy (24).

The first patient described with a mutation at codon 166 with substitution of cysteine by phenylalanine (C166F) presented with neonatal diabetes, full DEND syndrome and dysmorphic features including prominent metopic suture, bilateral ptosis and down turned mouth, but she died from aspiration pneumonia at the age of 6 months after partial and transitory control of epilepsy with tobtumamide (0.75 mg/kg/d) combined with ACTH therapy (26, 27). Afterwards, Flanagan et al. (19) demonstrated the C166Y mutation (substitution of cysteine by tyrosine) in our patient, followed by another case (C166Y) described by Suzuki et al. (28) of neonatal diabetes with DEND syndrome, dysmorphic facial features and arthrogryposis who has been treated exclusively with insulin.

Kir6.2 is expressed in several tissues including pancreatic β-cell, brain, and skeletal muscle; Kir6.2 mutations associated with DEND syndrome are believed to be less sensitive to ATP than those that cause isolated diabetes, and functional studies supported a relationship between the site of the mutation and the ability of the channel to close in the presence of ATP (19,29).

The underlying molecular mechanism on the reduction of ATP sensitivity varies accordingly to the site of Kir6.2 mutations, which can be located in the ATP-binding site or in regions involved in channel gating. Some mutations may influence both ATP binding and gating, as well as the mechanism of signal transduction to channel closure (29,30). In this regard, Trapp and cols. (31) demonstrated experimentally that mutations at residue 166 that replace cysteine – an hydrophobic amino acid, by larger and less hydrophobic amino acids increased the channel open probability, suggesting that the altered intrinsic gating kinetics should be the primary channel defect in these cases, what explain the unresponsiveness to sulfonylurea therapy. Phenylalanine has a similar hydrophobicity to cysteine but is much larger, causing an increase in the channel open probability (31), and tyrosine is both larger and less hydrophobic than cysteine.

On the other hand, less severe phenotypes have been associated with mutations that cause defects in either ATP binding or gating (30). Thus, clinical phenotype will be determined mainly by the degree of channel activation rather than the gene involved (4).

In conclusion, we have demonstrated that a child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 gene was insensitive to glibenclamide. This lack of clinical response was observed both for diabetes control and neurological features.

Acknowledgements: The molecular genetic work in Exeter was supported by the Wellcome Trust. No other potential conflict of interest relevant to this article was reported.

REFERENCES

KCNJ11 Mutation and Glibenclamide Insensitivity
Della Manna et al.


Correspondence to:
Thais Della Manna
Av. Pedroso de Moraes, 427
05419-000 São Paulo SP
E-mail: thais.manna@icr.usp.br